SGMO
Price:
$2.155
Market Cap:
$449.63M
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical tria...[Read more]
Industry
Biotechnology
IPO Date
2000-04-06
Stock Exchange
NASDAQ
Ticker
SGMO
According to Sangamo Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -3.04. This represents a change of -533.78% compared to the average of 0.70 of the last 4 quarters.
The mean historical PE Ratio of Sangamo Therapeutics, Inc. over the last ten years is -13.57. The current -3.04 PE Ratio has changed 2.14% with respect to the historical average. Over the past ten years (40 quarters), SGMO's PE Ratio was at its highest in in the December 2019 quarter at 53.24. The PE Ratio was at its lowest in in the September 2020 quarter at -215.06.
Average
-13.57
Median
-14.01
Minimum
-38.59
Maximum
-0.37
Discovering the peaks and valleys of Sangamo Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 681.48%
Maximum Annual PE Ratio = -0.37
Minimum Annual Increase = -85.42%
Minimum Annual PE Ratio = -38.59
Year | PE Ratio | Change |
---|---|---|
2023 | -0.37 | -85.42% |
2022 | -2.52 | -58.55% |
2021 | -6.08 | -64.89% |
2020 | -17.32 | 39.95% |
2019 | -12.38 | -24.00% |
2018 | -16.29 | -30.60% |
2017 | -23.47 | 681.48% |
2016 | -3.00 | -80.81% |
2015 | -15.65 | -59.45% |
2014 | -38.59 | 32.14% |
The current PE Ratio of Sangamo Therapeutics, Inc. (SGMO) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-2.99
5-year avg
-7.73
10-year avg
-13.57
Sangamo Therapeutics, Inc.’s PE Ratio is less than Editas Medicine, Inc. (-0.80), less than Intellia Therapeutics, Inc. (-2.85), less than bluebird bio, Inc. (-0.25), greater than Alnylam Pharmaceuticals, Inc. (-96.81), less than ImmunoGen, Inc. (322.18),
Company | PE Ratio | Market cap |
---|---|---|
-0.80 | $168.81M | |
-2.85 | $1.50B | |
-0.25 | $76.28M | |
-96.81 | $32.26B | |
322.18 | $8.73B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Sangamo Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Sangamo Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Sangamo Therapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for Sangamo Therapeutics, Inc. (SGMO)?
What is the highest PE Ratio for Sangamo Therapeutics, Inc. (SGMO)?
What is the 3-year average PE Ratio for Sangamo Therapeutics, Inc. (SGMO)?
What is the 5-year average PE Ratio for Sangamo Therapeutics, Inc. (SGMO)?
How does the current PE Ratio for Sangamo Therapeutics, Inc. (SGMO) compare to its historical average?